4.4 Review

SARS-CoV-2 therapeutics: how far do we stand from a remedy?

Journal

PHARMACOLOGICAL REPORTS
Volume 73, Issue 3, Pages 750-768

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s43440-020-00204-0

Keywords

Antiviral; COVID-19; Drug repurposing; SARS-CoV-2; Target proteins

Funding

  1. Ram Lal Anand College

Ask authors/readers for more resources

The global outbreak of SARS-CoV-2 has triggered the urgent need for effective pharmacological interventions. Clinical trials and laboratory studies have shown promising results, but the virus's RNA nature and potential for mutation pose challenges for drug resistance. The review focuses on potential drug targets within the virus and the importance of developing a cocktail therapy to combat drug resistance.
The SARS-CoV-2 has affected millions worldwide and has posed an immediate need for effective pharmacological interventions. Ever since the outbreak was declared, the medical fraternity across the world is facing a unique situation of offering assistance and simultaneously generating reliable data with high-quality evidence to extend the scope of finding a treatment. With no proven vaccine or other interventions available hitherto, there is a frenzied urgency of sharing preliminary data from laboratories and trials to shape a global response against the virus. Several clinical trials with investigational and approved repurposed therapeutics have shown promising results. This review aims to compile the information of the reported molecules approved for emergency use and those under clinical trials and still others with good results in the studies conducted so far. Being an RNA virus, SARS-CoV-2 is prone to mutation; thus, the possibility of gaining resistance to available drugs is high. Consequently, a cocktail therapy based on drug interaction with different stages of its replicative cycle is desirable to reduce the chances of evolving drug resistance. Since this virus encodes several proteins, including 16 nonstructural and 4 structural proteins, this review also offers an insight into potential drug targets within SARS-CoV-2.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available